![Charles Li](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 275 088 $ am 31.05.2026
Dr. Charles Li is a Chief Business Officer at Angel Pharmaceuticals Co., Ltd. and an Independent Director at Ekso Bionics Holdings, Inc. He is on the Board of Directors at Ekso Bionics Holdings, Inc. He received his undergraduate degree from Xi'an Jiaotong University and a doctorate degree from John A Paulson School of Engineering & Applied Sciences.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0,42 % | 20.02.2026 | 14.983 ( 0,42 % ) | 275 088 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
Angel Pharmaceuticals Co., Ltd.
 Angel Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops medicines for treatment of cancer, autoimmune and infectious diseases | Corporate Officer/Principal | 10.10.2020 |
| Unternehmen | Position | Ende |
|---|---|---|
| EKSO BIONICS HOLDINGS | Direktor/Vorstandsmitglied | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 4 |
|---|---|
Ekso Bionics Holdings, Inc.
 Ekso Bionics Holdings, Inc. Medical SpecialtiesHealth Technology Operates as a robotic exoskeleton company, which designs and develops exoskeletons and wearable robots | Health Technology |
Xi'an Jiaotong University
 Xi'an Jiaotong University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
John A Paulson School of Engineering & Applied Sciences
 John A Paulson School of Engineering & Applied Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Angel Pharmaceuticals Co., Ltd.
Angel Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops medicines for treatment of cancer, autoimmune and infectious diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
